Id-specific T-cell response (proliferation/cytokine production) and M-component concentration in myeloma patients immunized with the autologous tumor-derived Id Ig in combination with adjuvant cytokines
. | Wk 0 . | . | . | Wk 4* . | . | Wk 8/10 . | . | . | Wk 14/16 . | . | . | Wk 30 . | . | . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients (adjuvant cytokine) . | Prol† . | E‡ . | M§ . | Prol . | E . | Prol . | E . | M . | Prol . | E . | M . | Prol . | E . | M . | |||||||||
| MM-1 (IL-12) | Neg | Neg | 25 | 8 | Neg | 179 | 78 | ND | 64 | 11 | 35 | Neg | Neg | 34 | |||||||||
| MM-2(IL-12/GM) | Neg | Neg | 22 | 91 | Neg | 44 | Neg. | ND | 36 | Neg. | 26 | Neg | Neg | 29 | |||||||||
| MM-3 (IL-12) | Neg | Neg | 34 | Neg | Neg | Neg | Neg | ND | Neg | Neg | 30 | Neg | Neg | 37 | |||||||||
| MM-4(IL-12/GM) | 18 | Neg | 17 | 71 | Neg | 101 | Neg | ND | 11 | Neg | 17 | Neg | ND | 16 | |||||||||
| MM-5(IL-12/GM) | Neg | Neg | 30 | Neg | Neg | 84 | Neg | ND | 81 | 70 | 28 | 54 | 25 | 44 | |||||||||
| MM-6 (IL-12) | 14 | Neg | 20 | Neg | Neg | Neg | Neg | ND | Neg | Neg | 21 | ND | ND | ND | |||||||||
. | Wk 0 . | . | . | Wk 4* . | . | Wk 8/10 . | . | . | Wk 14/16 . | . | . | Wk 30 . | . | . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients (adjuvant cytokine) . | Prol† . | E‡ . | M§ . | Prol . | E . | Prol . | E . | M . | Prol . | E . | M . | Prol . | E . | M . | |||||||||
| MM-1 (IL-12) | Neg | Neg | 25 | 8 | Neg | 179 | 78 | ND | 64 | 11 | 35 | Neg | Neg | 34 | |||||||||
| MM-2(IL-12/GM) | Neg | Neg | 22 | 91 | Neg | 44 | Neg. | ND | 36 | Neg. | 26 | Neg | Neg | 29 | |||||||||
| MM-3 (IL-12) | Neg | Neg | 34 | Neg | Neg | Neg | Neg | ND | Neg | Neg | 30 | Neg | Neg | 37 | |||||||||
| MM-4(IL-12/GM) | 18 | Neg | 17 | 71 | Neg | 101 | Neg | ND | 11 | Neg | 17 | Neg | ND | 16 | |||||||||
| MM-5(IL-12/GM) | Neg | Neg | 30 | Neg | Neg | 84 | Neg | ND | 81 | 70 | 28 | 54 | 25 | 44 | |||||||||
| MM-6 (IL-12) | 14 | Neg | 20 | Neg | Neg | Neg | Neg | ND | Neg | Neg | 21 | ND | ND | ND | |||||||||
Negative indicates a value below the cutoff level; ND, not done.
M-component concentration was not analyzed at week 4.
Proliferation assay expressed as stimulation index; ≥ 3.1 was considered a positive response.
ELISPOT (IFN-γ production) expressed as number of spots/105 PBMCs; ≥ 10 was considered a positive response.
Serum M-component concentration (g/L).